Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Bug

Showing results (231-240 of 319) with videos related to

Pageof 32
Sort By:
Transplantation and Cellular Therapy|December 17, 2025
Pretransplant HMA and Venetoclax in AML patients - a Real-World Analysis from the Cooperative Transplant Study GroupChristina Rautenberg, Matthias Stelljes, Gesine Bug, et al.
Plos One|January 10, 2013
Feasibility of azacitidine added to standard chemotherapy in older patients with acute myeloid leukemia--a randomised SAL pilot studyUtz Krug, Anja Koschmieder, Daniela Schwammbach, et al.
The British Journal of Radiology|September 27, 2014
Future development of biologically relevant dosimetryH Palmans, H Rabus, A L Belchior, et al.
Haematologica|September 18, 2012
Influence of molecular subgroups on outcome of acute myeloid leukemia with normal karyotype in 141 patients undergoing salvage allogeneic stem cell transplantation in primary induction failure or beyond first relapseTim Pfeiffer, Michael Schleuning, Jiri Mayer, et al.
The European Journal of Health Economics : HEPAC : Health Economics in Prevention and Care|February 15, 2026
Healthcare resource utilization and costs of letermovir for cytomegalovirus-prophylaxis after allogeneic hematopoietic cell transplantation in a real-world, multi-centre study in GermanyMarie Engelhard, Sebastian M Wingen-Heimann, Annika Y Classen, et al.
Blood|March 22, 2014
Outcome of patients with abnl(17p) acute myeloid leukemia after allogeneic hematopoietic stem cell transplantationJan M Middeke, Min Fang, Jan J Cornelissen, et al.
Annals of Hematology|April 11, 2012
Prognostic significance of combined MN1, ERG, BAALC, and EVI1 (MEBE) expression in patients with myelodysplastic syndromesFelicitas Thol, Haiyang Yun, Ann-Kathrin Sonntag, et al.
Bone Marrow Transplantation|July 3, 2024
Tacrolimus versus cyclosporine a combined with post-transplantation cyclophosphamide for AML In first complete remission: a study from the acute leukemia working party (EBMT)Gesine Bug, Myriam Labopin, Alexander Kulagin, et al.
The Lancet. Haematology|April 10, 2018
Enhanced labile plasma iron and outcome in acute myeloid leukaemia and myelodysplastic syndrome after allogeneic haemopoietic cell transplantation (ALLIVE): a prospective, multicentre, observational trialMartin Wermke, Julia Eckoldt, Katharina S Götze, et al.
Nature Biotechnology|November 9, 2007
The OBO Foundry: coordinated evolution of ontologies to support biomedical data integrationBarry Smith, Michael Ashburner, Cornelius Rosse, et al.
Pageof 32

Showing results (231-240 of 319) with videos related to

Sort By:
Pageof 32
Transplantation and Cellular Therapy|December 17, 2025
Pretransplant HMA and Venetoclax in AML patients - a Real-World Analysis from the Cooperative Transplant Study GroupChristina Rautenberg, Matthias Stelljes, Gesine Bug, et al.
Plos One|January 10, 2013
Feasibility of azacitidine added to standard chemotherapy in older patients with acute myeloid leukemia--a randomised SAL pilot studyUtz Krug, Anja Koschmieder, Daniela Schwammbach, et al.
The British Journal of Radiology|September 27, 2014
Future development of biologically relevant dosimetryH Palmans, H Rabus, A L Belchior, et al.
Haematologica|September 18, 2012
Influence of molecular subgroups on outcome of acute myeloid leukemia with normal karyotype in 141 patients undergoing salvage allogeneic stem cell transplantation in primary induction failure or beyond first relapseTim Pfeiffer, Michael Schleuning, Jiri Mayer, et al.
The European Journal of Health Economics : HEPAC : Health Economics in Prevention and Care|February 15, 2026
Healthcare resource utilization and costs of letermovir for cytomegalovirus-prophylaxis after allogeneic hematopoietic cell transplantation in a real-world, multi-centre study in GermanyMarie Engelhard, Sebastian M Wingen-Heimann, Annika Y Classen, et al.
Blood|March 22, 2014
Outcome of patients with abnl(17p) acute myeloid leukemia after allogeneic hematopoietic stem cell transplantationJan M Middeke, Min Fang, Jan J Cornelissen, et al.
Annals of Hematology|April 11, 2012
Prognostic significance of combined MN1, ERG, BAALC, and EVI1 (MEBE) expression in patients with myelodysplastic syndromesFelicitas Thol, Haiyang Yun, Ann-Kathrin Sonntag, et al.
Bone Marrow Transplantation|July 3, 2024
Tacrolimus versus cyclosporine a combined with post-transplantation cyclophosphamide for AML In first complete remission: a study from the acute leukemia working party (EBMT)Gesine Bug, Myriam Labopin, Alexander Kulagin, et al.
The Lancet. Haematology|April 10, 2018
Enhanced labile plasma iron and outcome in acute myeloid leukaemia and myelodysplastic syndrome after allogeneic haemopoietic cell transplantation (ALLIVE): a prospective, multicentre, observational trialMartin Wermke, Julia Eckoldt, Katharina S Götze, et al.
Nature Biotechnology|November 9, 2007
The OBO Foundry: coordinated evolution of ontologies to support biomedical data integrationBarry Smith, Michael Ashburner, Cornelius Rosse, et al.
Pageof 32